These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

10178 related items for PubMed ID: 12969539

  • 1. [Melanoma antigen genes(MAGE) and malignant tumors].
    Xu JZ, Lin S.
    Ai Zheng; 2003 Sep; 22(9):1001-4. PubMed ID: 12969539
    [Abstract] [Full Text] [Related]

  • 2. The potential of melanoma antigen expression in cancer therapy.
    Gillespie AM, Coleman RE.
    Cancer Treat Rev; 1999 Aug; 25(4):219-27. PubMed ID: 10448130
    [Abstract] [Full Text] [Related]

  • 3. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
    Huang LQ, Brasseur F, Serrano A, De Plaen E, van der Bruggen P, Boon T, Van Pel A.
    J Immunol; 1999 Jun 01; 162(11):6849-54. PubMed ID: 10352307
    [Abstract] [Full Text] [Related]

  • 4. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
    Zhang XM, Zhang YF, Huang Y, Qu P, Ma B, Si SY, Li ZS, Li WX, Li X, Ge W, Hu PZ, Sui YF.
    Oncol Rep; 2008 Jul 01; 20(1):245-52. PubMed ID: 18575744
    [Abstract] [Full Text] [Related]

  • 5. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R, Ronteltap C, Heuveling M, Debets R, Bolhuis R.
    Gene Ther; 2005 Jan 01; 12(2):140-6. PubMed ID: 15496961
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors.
    Corbière V, Nicolay H, Russo V, Stroobant V, Brichard V, Boon T, van der Bruggen P.
    Tissue Antigens; 2004 May 01; 63(5):453-7. PubMed ID: 15104676
    [Abstract] [Full Text] [Related]

  • 8. The melanoma antigen genes--any clues to their functions in normal tissues?
    Ohman Forslund K, Nordqvist K.
    Exp Cell Res; 2001 May 01; 265(2):185-94. PubMed ID: 11302683
    [Abstract] [Full Text] [Related]

  • 9. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.
    Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B.
    Hum Immunol; 2004 Aug 01; 65(8):794-802. PubMed ID: 15336780
    [Abstract] [Full Text] [Related]

  • 10. Melanoma-associated antigen genes - an update.
    Sang M, Wang L, Ding C, Zhou X, Wang B, Wang L, Lian Y, Shan B.
    Cancer Lett; 2011 Mar 28; 302(2):85-90. PubMed ID: 21093980
    [Abstract] [Full Text] [Related]

  • 11. Investigation of the expression of melanoma antigen-encoding genes (MAGE-A1 to -A6) in oral squamous cell carcinomas to determine potential targets for gene-based cancer immunotherapy.
    Ries J, Schultze-Mosgau S, Neukam F, Diebel E, Wiltfang J.
    Int J Oncol; 2005 Mar 28; 26(3):817-24. PubMed ID: 15703841
    [Abstract] [Full Text] [Related]

  • 12. [Analysis of tumor rejection antigen peptides recognized by specific CTL].
    Uenaka A, Nakayama E.
    Nihon Rinsho; 1996 Jan 28; 54(1):242-9. PubMed ID: 8587197
    [Abstract] [Full Text] [Related]

  • 13. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities.
    Connerotte T, Van Pel A, Godelaine D, Tartour E, Schuler-Thurner B, Lucas S, Thielemans K, Schuler G, Coulie PG.
    Cancer Res; 2008 May 15; 68(10):3931-40. PubMed ID: 18483279
    [Abstract] [Full Text] [Related]

  • 14. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
    Zhang Y, Renkvist N, Sun Z, Schuler-Thurner B, Glaichenhaus N, Schuler G, Boon T, van der Bruggen P, Colau D.
    Eur J Immunol; 2005 Apr 15; 35(4):1066-75. PubMed ID: 15756643
    [Abstract] [Full Text] [Related]

  • 15. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
    Akiyama Y, Maruyama K, Tai S, Komiyama M, Iizuka A, Takikawa M, Ohshita C, Yamamoto A, Yamazaki N, Kiyohara Y, Yamaguchi K.
    Anticancer Res; 2009 Feb 15; 29(2):647-55. PubMed ID: 19331215
    [Abstract] [Full Text] [Related]

  • 16. [Tumor rejection antigen and cancer immunotherapy].
    Matsutake T, Nakayama E.
    Gan To Kagaku Ryoho; 1995 Nov 15; 22(13):1871-7. PubMed ID: 7487115
    [Abstract] [Full Text] [Related]

  • 17. Immune characterization of clinical grade-dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes.
    Trakatelli M, Toungouz M, Lambermont M, Heenen M, Velu T, Bruyns C.
    Cancer Gene Ther; 2005 Jun 15; 12(6):552-9. PubMed ID: 15665821
    [Abstract] [Full Text] [Related]

  • 18. Tumor antigen expression in melanoma varies according to antigen and stage.
    Barrow C, Browning J, MacGregor D, Davis ID, Sturrock S, Jungbluth AA, Cebon J.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):764-71. PubMed ID: 16467087
    [Abstract] [Full Text] [Related]

  • 19. [Identification of cancer antigens of relevance for specific cancer immunotherapy].
    van den Eynde B.
    Bull Mem Acad R Med Belg; 2001 Feb 01; 156(10-12):548-55. PubMed ID: 12371273
    [Abstract] [Full Text] [Related]

  • 20. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
    van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, Liénard D, Speiser D, Marchand M, Brichard VG, Escudier B, Négrier S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulie PG, Boon T.
    J Clin Oncol; 2005 Dec 10; 23(35):9008-21. PubMed ID: 16061912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 509.